Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Yo shushi
Read the transcript below the video
It says AACI
👍
On the tweet transcript
Ellen states:
“We will be updating on this compound at the AACI in San Diego in early April.”
It’s the AACR in San Diego in April not AACI.
The AACI conference 2024 AACI/CCAF Annual Meeting, October 20-22, at Loews Chicago.
But AACI Abstract requirements dates:
February 1, 2024
Online submission tool opens
March 4, 2024 - 5:00 pm Pacific time
Deadline to submit abstracts
April 2024
Abstracts selected for oral presentation; notifications sent to submitting authors
Could Avacta submitting another poster in October.
Twitter
Ophidian
“Once the Pfizer takeover of Seagen is all cleaned up, the the Seagen warhead MMAE (that #AVCT have mentioned a few times before) can be popped on to pre|CISION.
I suspect the takeover screwed up timing on this before”
Myles
💯this.
I would hope only a delay, not a pulling out, as the new exec team goes over the fine details and checks SeaGen's DD on Avacta and pre | CISION, before getting approval of the Pfizer board.
Assuming of course we're actually on the money with SeaGen being the possible partner for Avacta!
B2HS2L
Here is tweet transcript below
https://avacta.wistia.com/medias/1h18nhz59w
“ We're highly encouraged by the early data being produced in our lead compound, and we're looking forward to those new cyotoxics, on the precision platform that will be in our pipeline soon.“
(new cyotoxics) not talking about AVA6k
Could this be a hint of a LD 😉
CJ
They are the 2 quotes I picked up from the tweet.
Like telling the trolls to FO
Update at AACR
Dox is Dox
“ And we cleave in such a way that we release doxorubicin exactly as normal doxorubicin. So it's now able to do what doxorubicin does, which is go into cells, and kill them.”
“ So AVA6000 has been through a phase 1 clinical trial. Reported in December, we've had a favourable safety profile and have seen improvement in toxicities compared to doxorubicin. And this has been in mild, toxicities as well as more severe events. We've also seen preliminary evidence for efficacy. We will be updating on this compound at the AACI in San Diego in early April.”
Dogs are back
Some major networking sessions at the AACR.
OCE experts will take part Regulatory Science and Policy (RSP) sessions, held in the San Diego Convention Center, Upper Level, Room 1, as well as other events listed below. Times are listed as Pacific Time.
https://www.fda.gov/about-fda/oncology-center-excellence/oce-public-
“I can't believe there are still some here that believe AS had any input in the level of the raise.”
He is the CEO ffs
He agreed for raise now instead of months ago.
He agreed to 34% discount which city boys jumped on and drove the raise down to 50p
Wynbore FO my thread
Smith & Gardiner have got a couple of months to save their jobs.
If this SP hasn’t recovered by the AGM they are gone.
I think Gardiner has gone anyway, he is out of his depth and has got Stifel taking the pi55 out of him.
Smith back on the tools in the Lab.
That placing was the unforgivable….
Still No apology.
Finding STS patients shouldn’t be a problem in UK
Royal Marsden
Sarcoma Unit is one of the largest soft-tissue sarcoma units in Europe
The Sarcoma Unit now registers more than 850 patients a year.
https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/clinical-units/sarcoma-unit/sarcoma-unit-research-and-clinical
https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/clinical-units/sarcoma-unit
This is why AVA6000 is going to be approved and the 2W trial and P2 is just a boxticking exercise.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058915/
Thus, the prognosis of advanced STS remains dismal, and new drugs are needed
a median progression-free survival (PFS) of 8 months
AVA6000 Patient with 65% reduction has smashed this PFS.
Very interesting podcast on
FDA discussion on trial design and end points ,Project Optimus plus a mention on Accelerated approval.
30 mins apple podcast but well worth a listen.
https://t.co/8tIQiDIrzd
“We would like to apologise to our long term and very loyal supporters, many of you have supported us for years.
Under very challenging unprecedented market conditions at the moment,we have to raise at 50p to help keep the lights on moving forward.
Critically, this financing provides with us 12 months of cash runway.
I guarantee that the person doing our finances and myself will both step down if we need more in the next 12 months.
Again to our long term and very loyal supporters, I apologise again for this diabolical situation.”
( That was me telling my customers last night I put 50p on a Pie and a pint deal.
At least I apologised )
N. Kinnersley,
Avacta Grant/Contract, Paid consultant.
His company KK
Octa Consulting Services
Regulatory Authority Preparation
Octa provide consultancy to project teams on how to prepare for high-stakes meetings such as Regulatory Health Authorities, Due Diligence assessments or whenever the interpretation of data is key. We have provided in-meeting biostats contributions to key Regulatory Authorities, the list of which includes: FDA, EMA, German, Spanish, Swedish, Swiss, Australian, and Japanese. The disease areas most recently supported include Oncology, Haematology and rare respiratory diseases. Octa can provide Due Diligence assessments for collaborations or mergers as well as Quality Inspections or audits of CROs with regards to statistics and statistical programming activities.
Octa Consulting Services provide design, planning, implementation, and analyses of CDPs or individual clinical trials. From ‘First-in-Human’ studies to regulatory approvals, Octa Consulting Services will work with its partners to ensure a relevant and applicable evolution of the CDP. We have experience in a number of key disease areas including novel or orphan diseases. Octa Consulting Services work in both traditional designs (e.g. 3+3, SAD/MAD, parallel group Phase 3 etc) and also a range of adaptive and/or emerging designs such as the increasingly popular BOIN design in Phase 1.
https://octaconsulting.com/team
AACR
going to be interesting
Professor Paul Loadman
Pharmacokinetics ,Biopsy consultant
Nelson Kinnersley
Regulatory Authorities consultant.
Hope they help getting the SP back over £1.00 and beyond
Start getting LTH’s money back in the black.
Paul Loadman
Professor of Pharmacokinetics and Drug Metabolism at University of Bradford
P. Loadman,
Avacta Grant/Contract, Paid consultant.
G. Lahu,
ThinkQ2 AG Employment.
Avacta Grant/Contract, Paid consultant.
H. S. Jones,
Avacta Grant/Contract, Paid consultant.
N. Kinnersley,
Avacta Grant/Contract, Paid consultant.
F. McLaughlin,
Avacta Employment.
C. Twelves,
MSD, Eisai, Daiichi-Sankyo, AstraZeneca, Pfizer, Lilly, Novartis and Gilead Grant/Contract, Travel, Advisory boards and research funding.
Abstract
Abstract is embargoed at this time.
Why would they fly him out to AACR this has got to be AVA6000 trial.
“We have also successfully monitored low concentrations of highly potent metabolites and pharmacodynamic markers in small clinical biopsy samples as in a recent Phase I clinical trial.”
Drug metabolism and pharmacokinetics
ICT has an experienced Drug Metabolism and Pharmacokinetic (DMPK) Team, led by Prof Paul Loadman, who have worked on numerous contract research projects with industrial partners within efficient and well-resourced GCP laboratories. The team undertake analytical method development (LC-MS/MS) and a range of bioavailability and pharmacokinetic studies from simple evaluation of parent molecule in plasma to full ADME and tissue distribution.
Advantages of working with the DMPK team at ICT:
* Excellent knowledge and experience in this area- expert opinion from leading academics
* GCP accredited laboratories and high quality research and reporting
* Projects are managed to meet commercial timelines and we ensure our partners are fully updated on progress
* Examples of studies include the analysis of complex metabolic profiles and the development of analytical methods for the PK analysis of highly reactive and potent molecules in the picomolar range.
We have also successfully monitored low concentrations of highly potent metabolites and pharmacodynamic markers in small clinical biopsy samples as in a recent Phase I clinical trial.
Look who Avacta is flying out to AACR
P. Loadman,
Avacta Grant/Contract, Paid consultant.
https://www.abstractsonline.com/pp8/#!/20272/presentation/11478
Are they taking him to talk about the biopsy samples to BP.
Bella read the RNS below:
We have a patient still going from 3rd Cohort
The 59 year old with 65% reduction in tumour.
That’s massive that’s why I’m still in…….
28 Feb 2024 16:41
RNS Number : 8447E
The SDMC approved dose escalation to 120 mg/m2 in a second cohort, 160 mg/m2 in a third cohort, 200mg/m2 in a fourth cohort, 250mg/m2 in a fifth cohort, 310mg/m2 in a sixth cohort and 385mg/m2 in a seventh and final cohort.
A 59-year-old male with the diagnosis of undifferentiated pleomorphic sarcoma, treated at 160 mg/m2 on a three-weekly dosing ("Q3W"), resulted in a Partial Response with a duration of greater than 6 months and a tumour volume reduction of ~65%. Treatment is ongoing, with high FAP expression observed in the tumour tissue and a favourable PK profile with reduction in AUC which permits dosing for 7 additional cycles (~21 weeks)